Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Oct 5, 2026--

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the launch of Premia™ Precision, a new quality standard for elastomer components, designed to support sensitive and high-value injectable therapies and help pharmaceutical manufacturers advance their quality and regulatory objectives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005964910/en/

As injectable therapies, including biologics and GLP-1 therapies, become increasingly complex and valuable, expectations for primary packaging components are evolving beyond baseline regulatory requirements, with manufacturers placing greater focus on component quality, consistency and control.

Premia™ Precision is built on a comprehensive quality approach that combines impact-based quality criteria, risk-driven manufacturing controls, stringent visible and subvisible particle management, production data monitoring and 100% automated vision inspection of every component. Together, these capabilities establish a clearly defined quality standard focused on the attributes that matter most for high-value and sensitive injectable therapies, helping pharmaceutical manufacturers strengthen component consistency and manage quality risk.

Beatrice Leprince, President, Aptar Pharma Injectables, said, “As injectable therapies become more complex and valuable, pharmaceutical manufacturers need component quality standards that reflect increasingly demanding expectations for consistency and performance. Premia™ Precision demonstrates our commitment to advancing quality for sensitive injectable applications by combining our elastomer expertise, industrial capabilities and a rigorous approach to defect prevention and control.”

Nicolas Voisin, Senior Global Quality Director, Injectables, Aptar Pharma, added, “Premia™ Precision brings together impact-based quality limits, robust operational controls and 100% vision inspection in one standard. Together, these measures support a consistent approach to component quality throughout production and final verification.”

With a broad portfolio spanning elastomeric components, advanced coatings, ready-to-use technologies and aseptic transfer solutions for vial, pre-filled syringe and auto-injector applications, Aptar Pharma supports the development, manufacturing and delivery of injectable therapies from early development through commercialization.

Aptar Pharma’s injectables business combines over 60 years of precision manufacturing with expertise that extends beyond individual components to the broader injectable system. Backed by a customer-focused approach, Aptar Pharma works closely with pharmaceutical companies to address complex challenges, accelerate decision-making and deliver confidence throughout the injectable journey. Premia™ Precision represents the latest evolution of these capabilities, strengthening Aptar Pharma’s support for demanding injectable applications.

Aptar Pharma is officially launching Premia™ Precision at CPHI Milan, October 6-8, and at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Palm Springs, California, October 6-7, where attendees can meet with Aptar Pharma’s team of injectables experts to learn more about this new quality standard.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Aptar Pharma’s Premia™ Precision, a new quality standard for demanding injectable therapies. Image courtesy of Aptar Pharma

Russian authorities have quarantined a hospital and are monitoring contacts of an employee at a plague research institute in Siberia who contracted pneumonia of an “unknown” cause. Local state TV said the woman died last week.

Russian authorities said they found no evidence that her illness was caused by any of the pathogens she worked with. But the case has raised alarm in Russia after unconfirmed media reports suggested she might have died of pneumonic plague — a less common but severe form of plague that can spread from person to person.

The woman worked at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East in Irkutsk, southeastern Siberia. A state TV station in Irkutsk reported Monday that she died last week in a hospital in Shelekhov, a town just outside Irkutsk.

The hospital has been placed under quarantine, Mayor Maxim Modin said Friday, no longer admitting or discharging patients, and its laboratory halted carrying out routine tests. The hospital's outpatient clinic kept operating as usual, he said.

Anna Popova, head of Russia’s public health watchdog, Rospotrebnadzor, flew to Irkutsk and met with Gov. Igor Kobzev and other officials on Friday.

Kobzev said everyone who came into contact with the woman is under medical supervision. He didn’t identify the infection and called it a suspected case of “a particularly dangerous infection.”

Rospotrebnadzor was implementing “a full range of anti-epidemic measures,” he added.

Rospotrebnadzor said Sunday the woman was diagnosed with “pneumonia of unknown etiology,” or origin, and said “extensive” testing found “no microorganisms associated with the patient’s professional activities.”

The agency also said it didn't uncover any incidents at the institute “involving pathogenic microorganisms."

Two people who were in contact with the woman tested positive for a virus that causes a common cold and two others for COVID-19, the agency said, adding that others who were tested were all negative.

U.S. Secretary of State Marco Rubio said Monday he doesn’t think there is cause for alarm, but the U.S. is watching the case closely, aware that “it could spread quickly” despite the quarantine and other public health protocols.

Independent local news outlet Lyudi Baikala quoted sources it did not identify as saying the 28-year-old lab technician died from pneumonic plague and that several Irkutsk hospitals were placed under quarantine.

Asked Monday to comment on the case, Kremlin spokesman Dmitry Peskov said the public and media should follow official statements from Rospotrebnadzor, rather than "rumors or speculation.”

The Irkutsk Aluminum Plant in Shelekhov required staff to wear masks as a precaution, its director Artyom Fominykh said Saturday on Telegram, calling for calm and adding: "Better be safe than sorry.”

The World Health Organization describes pneumonic plague as a less common but severe form of plague — a disease caused by Yersinia pestis, a bacterium usually found in small mammals and their fleas.

“In the event of a potential laboratory exposure, it would be normal to identify individuals who might have been exposed and to monitor them according to the assessed level of risk,” said Dr. Malick Gibani, clinical associate professor in bacterial vaccinology at the Imperial College London.

The scale of any monitoring program would depend on "the circumstances of the exposure and the number of people potentially affected,” Gibani said in a written comment.

Ian Jones, professor of virology at the University of Reading, said that “plague carries a huge history and is still present in many parts of the world, including Russia,” although because of modern living conditions and antibiotics, “its potential is therefore limited.”

——

AP reporter Matthew Lee in Washington contributed.

This undated photo released by the Irkutsk Anti-Plague Research Institute of Siberia and Far East, shows the institute workers in a lab. (The Irkutsk Anti-Plague Research Institute of Siberia and Far East via AP)